Dyne Therapeutics 

Dyne Therapeutics 

Yahoo Finance • yesterday

Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

High-stakes clinical trials define the 2026 landscape for Dyne Therapeutics (NASDAQ:DYN) and Viking Therapeutics (NASDAQ:VKTX). Both firms seek to revolutionize patient care while navigating the complex path toward regulatory approval. Dy... Full story

Yahoo Finance • 9 days ago

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., June 18, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announ... Full story

Yahoo Finance • 22 days ago

Dyne Therapeutics (DYN) Reaches Key Regulatory Milestone

Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 26, Dyne Therapeutics Inc. (NASDAQ:DYN) reached a major regulatory milestone by submitting its official Biologi... Full story

Yahoo Finance • 28 days ago

Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge

FCPM III Services B.V. disclosed a new position in Damora Therapeutics(NASDAQ:DMRA) as of March 31, 2026, acquiring 2,441,000 shares for an estimated $65.63 million based on quarterly average pricing. What happened According to a Securit... Full story

Yahoo Finance • 28 days ago

Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean

On May 15, 2026, FCPM III Services B.V. reported a sale of 818,460 shares of Dyne Therapeutics(NASDAQ:DYN), an estimated $14.11 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commis... Full story

Yahoo Finance • last month

Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

- Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion cohort of the DELIVER trial, treatment with z-rostudirsen resulted in a robust and statistically significant increase in... Full story

Yahoo Finance • last month

Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval

- 72-week trial will enroll approximately 90 participants; first site now open for enrollment - - Primary endpoint is rise from floor (RFF) velocity with multiple secondary endpoints to assess muscle and pulmonary function - - FORZETTO t... Full story

Yahoo Finance • last month

Dyne Therapeutics to Participate in Upcoming Investor Conferences

WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announc... Full story

Yahoo Finance • 2 months ago

Dyne Therapeutics GAAP EPS of -$0.73 beats by $0.04

* Dyne Therapeutics press release [https://seekingalpha.com/pr/20508820-dyne-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-highlights] (DYN [https://seekingalpha.com/symbol/DYN]): Q1 GAAP EPS of -$0.73 bea... Full story

Yahoo Finance • 3 months ago

Clearbridge Small Cap Growth Strategy Added Dyne Therapeutics (DYN) in Q4

ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” Q4 2025 investor letter. A copy of the letter can be downloaded here. The Strategy underperformed the Russell 2000 Growth Index... Full story

Yahoo Finance • 3 months ago

This Biotech Was Quietly Bought Before a $58 Per Share Takeout

On February 17, 2026, FCPM III Services B.V. disclosed a buy of 1,489,096 RAPT Therapeutics(NASDAQ:RAPT) shares, an estimated $46.24 million trade based on quarterly average pricing. What happened According to a Securities and Exchange C... Full story

Yahoo Finance • 4 months ago

Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)

- HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for enrollment - - Primary endpoint is the five... Full story

Yahoo Finance • 4 months ago

Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)

- New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on previously reported results demonstrating that z-rostudirsen treatment led to sustained... Full story

Yahoo Finance • 4 months ago

Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing

Key Points 209,523-share increase in Dyne Therapeutics; estimated transaction value $3.97 million (based on quarterly average pricing) Quarter-end position in Dyne Therapeutics rose $12.82 million in value, reflecting both trading and sto... Full story

Yahoo Finance • 4 months ago

Sarepta CEO To Jump Ship After 'Tumultuous' Year

Sarepta Therapeutics, Inc.(NASDAQ:SRPT) shares are down during Thursday’s premarket session as the company reported its fourth-quarter and full-year 2025 financial results. Over the last year, the company’s stock has plunged from $106.86... Full story

Yahoo Finance • 4 months ago

Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference

- Late-breaking poster to feature new positive cardiopulmonary function results from the DELIVER trial of z-rostudirsen in DMD - - Oral presentation on Phase 3 trial design for z-basivarsen in DM1 - - Five total presentations across thre... Full story

Yahoo Finance • 4 months ago

DYN Crosses Below Key Moving Average Level

In trading on Tuesday, shares of Dyne Therapeutics Inc (Symbol: DYN) crossed below their 200 day moving average of $14.86, changing hands as low as $14.67 per share. Dyne Therapeutics Inc shares are currently trading down about 2.6% on th... Full story

Yahoo Finance • 4 months ago

Dyne Therapeutics (DYN) Attains Orphan Drug Designation From Japanese Ministry

Dyne Therapeutics (NASDAQ:DYN) is one of the 17 biotechnology stocks with more than 50% upside. As of the February 12 closing, Dyne Therapeutics (NASDAQ:DYN) held a strongly bullish consensus view. Of the 9 analysts covering the stock, 7... Full story

Yahoo Finance • 5 months ago

Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors

BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the appointment of Carlo Incerti, M.D., to its Board of Directors, effective January 1, 2026. Dr. Incerti... Full story

Yahoo Finance • 6 months ago

Dyne Therapeutics Appoints Vikram Karnani to Board of Directors

WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announ... Full story